Katherine Cone1, Janell Lanpher1, Abigail Kinens1, Philomena Richard1, Sarah Couture1, Rebecca Brackin1, Emily Payne1, Kylee Harrington1, Kenner C Rice2, Glenn W Stevenson3,4. 1. Department of Psychology, University of New England, Biddeford, ME, 04005, USA. 2. Drug Design and Synthesis Section, Molecular Targets and Medications Branch, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Rockville, MD, 20850, USA. 3. Department of Psychology, University of New England, Biddeford, ME, 04005, USA. gstevenson@une.edu. 4. Center for Excellence in the Neurosciences, University of New England, Biddeford, Maine, 04005, USA. gstevenson@une.edu.
Abstract
RATIONALE AND OBJECTIVES: Although delta/mu receptor interactions vary as a function of behavioral endpoint, there have been no assessments of these interactions using assays of pain-depressed responding. This is the first report of delta/mu interactions using an assay of pain-depressed behavior. METHODS: A mult-cycle FR10 operant schedule was utilized in the presence of (nociception) and in the absence of (rate suppression) a lactic acid inflammatory pain-like manipulation. SNC80 and methadone were used as selective/high efficacy delta and mu agonists, respectively. Both SNC80 and methadone alone produced a dose-dependent restoration of pain-depressed responding and dose-dependent response rate suppression. Three fixed ratio mixtures, based on the relative potencies of the drugs in the nociception assay, also produced dose-dependent antinociception and sedation. Isobolographic analysis indicated that all three mixtures produced supra-additive antinociceptive effects and simply additive sedation effects. CONCLUSIONS: The therapeutic index (TI) inversely varied as a function of amount of SNC80 in the mixture, such that lower amounts of SNC80 produced a higher TI, and larger amounts produced a lower TI. Compared to literature using standard pain-elicited assays, the orderly relationship between SNC80 and TI reported here may be a unique function of assessing pain-depressed behavior.
RATIONALE AND OBJECTIVES: Although delta/mu receptor interactions vary as a function of behavioral endpoint, there have been no assessments of these interactions using assays of pain-depressed responding. This is the first report of delta/mu interactions using an assay of pain-depressed behavior. METHODS: A mult-cycle FR10 operant schedule was utilized in the presence of (nociception) and in the absence of (rate suppression) a lactic acidinflammatory pain-like manipulation. SNC80 and methadone were used as selective/high efficacy delta and mu agonists, respectively. Both SNC80 and methadone alone produced a dose-dependent restoration of pain-depressed responding and dose-dependent response rate suppression. Three fixed ratio mixtures, based on the relative potencies of the drugs in the nociception assay, also produced dose-dependent antinociception and sedation. Isobolographic analysis indicated that all three mixtures produced supra-additive antinociceptive effects and simply additive sedation effects. CONCLUSIONS: The therapeutic index (TI) inversely varied as a function of amount of SNC80 in the mixture, such that lower amounts of SNC80 produced a higher TI, and larger amounts produced a lower TI. Compared to literature using standard pain-elicited assays, the orderly relationship between SNC80 and TI reported here may be a unique function of assessing pain-depressed behavior.
Authors: Neil Schwartz; Paul Temkin; Sandra Jurado; Byung Kook Lim; Boris D Heifets; Jai S Polepalli; Robert C Malenka Journal: Science Date: 2014-08-01 Impact factor: 47.728
Authors: Henry I Mosberg; Larisa Yeomans; Jessica P Anand; Vanessa Porter; Katarzyna Sobczyk-Kojiro; John R Traynor; Emily M Jutkiewicz Journal: J Med Chem Date: 2014-03-26 Impact factor: 7.446
Authors: Michael D Leitl; David N Potter; Kejun Cheng; Kenner C Rice; William A Carlezon; S Stevens Negus Journal: Mol Pain Date: 2014-09-23 Impact factor: 3.395
Authors: David J Reiner; E Andrew Townsend; Javier Orihuel; Sarah V Applebey; Sarah M Claypool; Matthew L Banks; Yavin Shaham; S Stevens Negus Journal: Psychopharmacology (Berl) Date: 2021-03-25 Impact factor: 4.530
Authors: A N Baldwin; M L Banks; S A Marsh; E A Townsend; M Venniro; Y Shaham; S Stevens Negus Journal: Psychopharmacology (Berl) Date: 2022-01-19 Impact factor: 4.530
Authors: Julie A Meade; Alison N Fowlkes; Mackinsey J Wood; Mary Claire Kurtz; Madeline M May; Wisam B Toma; Urszula O Warncke; Jared Mann; Mohammed Mustafa; Aron H Lichtman; M Imad Damaj Journal: Behav Pharmacol Date: 2021-08-01 Impact factor: 2.277
Authors: Luke P Legakis; Clare M Diester; Edward A Townsend; Ladan Karim-Nejad; Sidney Stevens Negus Journal: Behav Pharmacol Date: 2020-08 Impact factor: 2.277